Posted by Michael Wonder on 03 Jun 2021
Quebec extends public reimbursement of Dupixent (dupilumab) for the treatment of moderate to severe atopic dermatitis to include adolescents
1 June 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec will now apply for Canadians aged 12 years and older when specific criteria are met.
Sanofi Canada is very pleased to announce that Quebec has extended its listing of Dupixent (dupilumab injection) under the Régie de l'assurance maladie du Québec to include public reimbursement for Canadians aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
